If a group of metabolic paediatricians had been asked 10 years ago which disorders they thought would be the most treatable at the start of the new millennium, very few would have mentioned lysosomal storage disorders (LSDs). The early onset, progressive nature, and tendency to involve the CNS have always been regarded as major hurdles to effective treatment. However, the final decade of the 20th century has seen developments in organ transplantation, enzyme replacement therapy (ERT), and gene transfer so that curative treatment for at least some of these disorders is no longer a distant goal.
The lysosome is an abundant membrane-bound vacuole found in almost all cells. It encloses an acid compartment generated by proton ATPase and houses the mature forms of a number of acid hydrolases which are important in cell digestion and recycling and in forming the terminal compartment in the endocytic pathway. At least 40 different disorders are associated with pathological storage of naturally occurring compounds within lysosomes. In some instances this is the result of a deficiency of a specific hydrolase and in others it is due to a defect in transport, either of the hydrolase to the organelle or of a specific compound out of the lysosome. Table I shows a breakdown of these disorders which, by convention, are usually classed according to the storage compound. There have been few comprehensive studies of the prevalence of LSDs as a group. Recent studies from Australia and the Netherlands suggest a combined prevalence of about 1 per 7500 live births, 1, 2 which makes LSDs twice as prevalent as phenylketonuria (PKU) in these communities.
The excellent text edited by Applegarth, Dimmick, and Hall 3 gives a general review of lysosomal structure and function.
A feature of the majority of LSDs is the great clinical variability in diseases associated with a single enzyme defect. There may be substantial variation in the age at which the disease becomes apparent, the rate at which functional deterioration occurs, and in the range of affected tissues. As a general rule, disease presenting in infancy or early childhood is associated with a more rapid progression of symptoms and a poorer prognosis, while late-onset disease may be compatible with a normal lifespan. These clinical features crystallize many of the issues facing a systematic approach to therapy in LSD, and can be summarized as a need to identify patients before the onset of irreversible pathology and for therapy to restore enzyme activity successfully in a broad range of tissues, including the CNS for some LSDs.
Treatment of LSDs

SUPPORTIVE THERAPY
Where curative therapy is not contemplated the aim is to improve quality of life of the patients by judicious surgeries and frequent careful assessment of their general condition. Supportive care has an important role in the management of all LSDs and until recently was all that could be offered to the majority of patients. A multidisciplinary approach is needed with other paediatric specialists as well as physiotherapists, dieticians, occupational therapists, and teachers being part of the therapy team. The family should receive appropriate community support, aids, adaptations, and help with financial claims. Genetic counselling is essential, as there is a risk of recurrence with all LSDs. ENZYME REPLACEMENT THERAPY There has been a resurgence of interest in ERT as a treatment for LSDs. Two factors contribute the most to this change of approach: first, the resounding success of ERT in type I Gaucher disease has revolutionized outcome in this disorder and second, the problems associated with prolonged gene expression following transfer in 'gene therapy' experiments have proven formidable, leading to a change of direction for some therapists.
ERT follows from the observation that many lysosomal enzymes can be secreted and then sequestrated by lysosomes in distant tissues and can be transferred to neighbouring cells by direct cellular contact. The circulation of lysosomal enzymes has been reviewed. 4, 5 In brief, the lysosomal protein is synthesized in the rough endoplasmic reticulum, transported to the Golgi following cleavage of a signal peptide, and transferred to the acidic prelysosomal compartment. At this point one of two things can happen: the protein can be segregated for immediate transfer to the lysosome or pass into a secretory pathway leading to release of the protein from the cell and then secondary reuptake via receptor mediated endocytosis into other cells. Uptake is primarily mediated via the mannose-6-phosphate receptor, although other receptors are implicated depending on cell and tissue.
Annotation
This internal enzyme circulation has been exploited successfully in the treatment of Gaucher disease (see Table I ). In this condition a deficiency of β-glucocerebrosidase leads to an accumulation of glucosylceramide within the deficient cell. Gaucher disease has all the typical clinical features of a LSD with early and late forms and a wide variety of phenotypic expression. The most prevalent form of the disease (type I, chronic non-neuronopathic) primarily affects the reticuloendothelial system and spares the CNS. Affected patients have a combination of bone marrow infiltration and failure, hepatosplenomegaly, and bone disease often leading to painful crises. Untreated, the disorder can be fatal and is a cause of long-term disability, especially due to the skeletal involvement in survivors. Early attempts at ERT in the 1970s were unsuccessful due to hepatic sequestration of the infused enzyme. 6 Increasing knowledge of normal lysosomal enzyme circulation led to modifications in the enzyme, which was initially purified from placentae (Ceredase ® , Genzyme Corporation, Boston, USA). Sequential deglycosylation of purified recombinant enzyme results in an enzyme with an exposed terminal mannose residue that targets the mannose lectin on macrophage plasma membranes (Cerezyme ® , Genzyme Corporation, Boston, USA). Studies have confirmed the efficacy and therapeutic similarity of intravenous Ceredase and Cerezyme. Cerezyme has the potential of being theoretically unlimited in supply and free of potential pathogenic contaminants. 7 Studies continue to try to find the optimum dosage regimen, 8 but there is no longer any doubt about efficacy and improvement in quality of life for treated patients. 9 Success in treating Gaucher disease has stimulated the development of ERT protocols for other LSDs and many of these are now at an advanced stage. The next enzyme likely to be available for clinical use is recombinant α-galactosidase. Phase III studies of the use of this preparation in Fabry disease have been recently reported 10 and these confirm the early clinical promise demonstrated in phase I and II studies. 11 At least one open-label phase III study has also been carried out into acid maltase deficiency. Early results suggest improvement and prolonged survival due to reversal of the cardiomyopathy in the infantile Pompe variant. 12 However, this is a generalized disorder and more prolonged follow-up is necessary before a firm statement can be made on longterm therapeutic benefits to other organs such as the CNS.
Mucopolysaccharidosis type I (MPS) was one of the first LSDs for which experimental therapy was considered and tried. Bone marrow transplantation (BMT) has been shown to alter the natural history of the severe variants of this disease, (MPS type IH -Hurler syndrome, see later). Most parents who have children with more attenuated forms of this condition (MPS type IH/S, Hurler/Scheie or IS, Scheie syndrome) are unwilling to consider BMT because of the associated risks and for these patients steady deterioration often leads to death or severe disability by early adulthood. ERT (given weekly by intravenous infusion) in a canine model of the disease suggested efficacy 13 and this has been confirmed in early human studies. 14 A phase III study started in January 2001 in the UK and other centres in Europe, Canada, and the USA.
ERT is also planned for Niemann-Pick B disease (sphingomyelinase deficiency), mucopolysaccharidosis type II (iduronate sulphatase deficiency, Hunter syndrome) and mucopolysaccharidosis type VI (galactosamine-4-sulphatase deficiency, Maroteux-Lamy syndrome), but these programmes are at an earlier stage of development.
What problems are anticipated with ERT? There will certainly be some patients who will develop antibodies to what, for them, are 'foreign' proteins. Fortunately this does not seem to have attenuated response to therapy in Gaucher disease 15 and strategies have been developed in this disorder for patients who have difficult antibody problems. 16 The other main issue with regard to therapy is cost. ERT will be impossible in some countries that have other major public health issues to deal with and a limited health budget. The development costs of ERT are high and, as a result, it is anticipated that the cost of therapy will be expensive. As more biotechnology companies become interested in this therapeutic approach, competition may drive prices downwards, but not enough to allow ERT to be regarded as a 'cheap' solution to the problems of LSDs. It is important that therapies are initiated and monitored by clinicians who are knowledgeable about the disease and the therapy to avoid a costly resource being abused.
BONE MARROW TRANSPLANTATION
The first BMT for a LSD took place 20 years ago 17 and it is surprising that the therapy still remains contentious to a number of clinicians. There can be no doubt that this therapy, while far from ideal, can favourably alter the natural history of a number of different LSDs including some that affect the CNS. In fact, 1981, almost every LSD has been treated by BMT somewhere in the world, with very variable results. The greatest experience is in mucopolysaccharidosis type IH (Hurler syndrome), with over 200 patients treated; most of the following discussion is specifically about this disorder. For other conditions and for a general discussion of the background to BMT there is an excellent review by Steward. 18 One of the biggest problems in interpreting the results of BMT was the uncontrolled way in which it was performed in the earliest days of therapy. Too many children were transplanted at a late age with less-than-perfect donors and so early results were dominated by the very negative experience of high mortality and many survivors developing severe learning difficulties. In MPS IH, early treatment by BMT (open to some debate but probably less than 18 months of age 19, 20 ) , can certainly protect the CNS from the neurodegenerative element of this disease. In addition, soft tissue correction occurs quickly with reduction in hepatosplenomegaly, improvement in cardiac function, and resolution of upper airways obstruction. [19] [20] [21] A big disappointment with treatment has been the very poor skeletal correction. The majority of patients require extensive orthopaedic and neurosurgical procedures to correct spinal deformity, hip dysplasia, and progressive genu valgum deformity. In the early days of treatment, these skeletal complications were not anticipated and the greatest deformity is probably seen in the older survivors. We are now much more proactive with regard to the bone disease and involve our specialist orthopaedic colleagues in management from a very early stage.
There are still a number of unresolved issues and despite the relatively long history as a therapy, BMT should continue to be considered as a treatment that is likely to be subject to technical improvement in years to come. In addition to solving the problem of poor skeletal response, challenges include the high incidence of graft rejection in MPS IH and other LSDs treated by BMT. Assessment needs to be made of the use of bone-marrow stromal cells as stem cells for nonhaematopoietic tissues (mesenchymal stem cells 22 ). Other possible future directions for this form of therapy are discussed in some detail in Steward's review. 18 
GENE THERAPY
Gene therapy is defined as the introduction of nucleic acids into cells to cure or treat a disease process (for a general review see the work of Fairbairn and Testa 23 ). In human studies more than 2000 patients have been enrolled in over 300 trials, but it is debatable whether any has shown any persistent therapeutic benefit. The majority of studies are phase I or phase II studies aimed at establishing efficacy in the treatment of malignant disease. The safety of such approaches in single gene disorders has recently been called into question with the death of a patient with ornithine carbamyl transferase deficiency treated with an adenoviral vector. 24 Of the various approaches that have been investigated with LSDs, haematopoietic stem cellmediated gene transfer has been the most studied. This would appear to be the best approach because of the existing experience with BMT. Such an approach has been accomplished in a number of mouse model systems leading to partial or complete correction of the disease phenotype. 25 A number of formidable challenges remain in humans. Persistence of expression and the need for efficient neurotropic vectors will be needed for most LSDs. Of some concern is the early indication of potential antibody problems after transfer of a gene identified as 'foreign' by a previously mutant patient. This may be more of a problem in patients with null mutations although this could not be predicted with any certainty. 26 
SUBSTRATE DEPRIVATION
The curative attempts at treatment described so far are aimed at correcting the genetic defect either directly by gene transfer, or indirectly by BMT, or by augmenting the missing enzyme with exogenous recombinant protein. Substrate deprivation therapy tackles the same problem by attempting to prevent the accumulation of the harmful substrate within the cell and thus restoring physiological balance between substrate and product. To be effective there must be some residual enzyme activity present in the patient's cells or no reversal of pathology could be anticipated. This is certainly found in many affected patients and indeed residual enzyme levels that are only a fraction of normal levels can protect an individual from developing a severe variant of a disorder.
One type of substrate deprivation therapy currently under trial aims at impairing the synthesis of glycosphingolipids (GSLs) to match the impaired rate of catabolism. Not only does it assume that there is some residual enzyme activity, but also that a partial deficiency of GSLs is compatible with normal health and development. Oral, daily, N-butyldeoxynojirimycin (OGT 918, Oxford Glycosciences, Abingdon, Oxfordshire) inhibits glucosyltransferase, a key enzyme in the synthesis of GSLs and has been used in both animal and human studies. In a study of 28 patients with non-neuronopathic Gaucher disease, clear evidence of efficacy was seen on a number of key clinical features. 27 Although side effects were seen in the study, in particular diarrhoea, the results justify further studies of this approach to treatment, especially as this form of small molecule therapy is potentially effective in diseases with a CNS component. A number of further studies are under development.
Conclusion
Although LSDs present formidable therapeutic challenges significant progress has been made in this area. Curative treatment seems a more realistic goal with LSDs than with other inborn errors of metabolism e.g. disorders of intermediary metabolism or mitochondrial disease to give just two examples. One can envisage combination therapies being used with one treatment modality supplemented or replaced by another as the circumstances of the patient or the disease change. Clinicians who manage patients with LSDs will have more tools in their therapeutic toolbox, but these will still have to be used carefully and correctly. Early diagnosis will become more essential, strengthening the case for neonatal screening for this group of conditions that are twice as prevalent as PKU.
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